Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Acid Suppressant Therapy: a Step Forward with Potassium-Competitive Acid Blockers
Carmelo Scarpignato, Richard H. Hunt
Current Treatment Options in Gastroenterology (2021) Vol. 19, Iss. 1, pp. 94-132
Open Access | Times Cited: 23

Showing 23 citing articles:

Management ofHelicobacter pyloriinfection: the Maastricht VI/Florence consensus report
Peter Malfertheiner, Françis Mégraud, Theodore Rokkas, et al.
Gut (2022) Vol. 71, Iss. 9, pp. 1724-1762
Open Access | Times Cited: 819
Vonoprazan: A Review in Helicobacter pylori Infection
Matt Shirley
Drugs (2024) Vol. 84, Iss. 3, pp. 319-327
Open Access | Times Cited: 12
Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments
Carmelo Scarpignato, Richard H. Hunt
Current Gastroenterology Reports (2024) Vol. 26, Iss. 11, pp. 273-293
Open Access | Times Cited: 9
Rapid diagnosis and precision treatment of Helicobacter pylori infection in clinical settings
Zeeshan Umar, Jia‐Wei Tang, Barry J. Marshall, et al.
Critical Reviews in Microbiology (2024), pp. 1-30
Closed Access | Times Cited: 8
The Protease Inhibitor Amprenavir Protects against Pepsin-Induced Esophageal Epithelial Barrier Disruption and Cancer-Associated Changes
Simon Blaine‐Sauer, Tina L. Samuels, Ke Yan, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6765-6765
Open Access | Times Cited: 11
Mathematical model of the relationship between pH holding time and erosive esophagitis healing rates
Colin W. Howden, Carmelo Scarpignato, Eckhard Leifke, et al.
CPT Pharmacometrics & Systems Pharmacology (2024)
Open Access | Times Cited: 4
Pharmacological management of gastro-esophageal reflux disease: state of the art in 2024
Pierfrancesco Visaggi, Luisa Bertin, Andrea Pasta, et al.
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 15, pp. 2077-2088
Closed Access | Times Cited: 4
Efficacy of Potassium-competitive Acid Blockers Versus Proton Pump Inhibitors for Gastric ulcers: Bayesian and frequentist Network Meta-analysis With Cross-inference Through a Quality management System
In Mo Yoon, Ki Jun Kim, Kwan-Haeng Lee, et al.
Current Therapeutic Research (2025) Vol. 102, pp. 100776-100776
Open Access
Phase I Study to Evaluate the Effect of Hepatic Impairment on Pharmacokinetics and Safety of Tegoprazan, a Potassium Competitive Acid Blocker
Anhye Kim, Dongseong Shin, Yongsang Seo, et al.
Advances in Therapy (2025)
Closed Access
Bridging the Gap between Chemistry and Medicine to Improve Medical Students’ Engagement and Learning Outcomes in General Chemistry
Zhonghong Yan, Chris Amodio, Fang Zhang, et al.
Journal of Chemical Education (2025)
Closed Access
A translational pharmacokinetic/pharmacodynamic approach supports optimal vonoprazan dosing for erosive oesophagitis and Helicobacter pylori infection
Carmelo Scarpignato, Colin W. Howden, Eckhard Leifke, et al.
Alimentary Pharmacology & Therapeutics (2023) Vol. 58, Iss. 1, pp. 16-25
Open Access | Times Cited: 8
Metabolites are overlooked in environmental risk assessments and monitoring of pharmaceuticals: The case study of pantoprazole
Finnian Freeling, Dominic Armbruster, Karsten Nödler, et al.
Water Research (2024) Vol. 256, pp. 121596-121596
Closed Access | Times Cited: 3
Safety of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease
Angela Tietto, Sofia Faggin, Carmelo Scarpignato, et al.
Expert Opinion on Drug Metabolism & Toxicology (2024), pp. 1-16
Closed Access | Times Cited: 3
Tiered approach to evaluate the CYP3A victim and perpetrator drug–drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling
Darcy J. Mulford, Diane Ramsden, Liming Zhang, et al.
CPT Pharmacometrics & Systems Pharmacology (2023) Vol. 12, Iss. 4, pp. 532-544
Open Access | Times Cited: 8
A Population Pharmacokinetic Model of Vonoprazan: Evaluating the Effects of Race, Disease Status, and Other Covariates on Exposure
Carmelo Scarpignato, Eckhard Leifke, Neila Smith, et al.
The Journal of Clinical Pharmacology (2021) Vol. 62, Iss. 6, pp. 801-811
Open Access | Times Cited: 18
The Current Role of Vonoprazan in Helicobacter pylori Treatment
Carlo A Fallone
Gastroenterology (2022) Vol. 163, Iss. 3, pp. 572-574
Open Access | Times Cited: 9
In Vitro Metabolism and Transport Characteristics of Zastaprazan
Min Seo Lee, Jihoon Lee, Minyeong Pang, et al.
Pharmaceutics (2024) Vol. 16, Iss. 6, pp. 799-799
Open Access | Times Cited: 1
Modern Approaches to <i>H. pylori</i> Eradication Therapy in Adults (Literature Review and Resolution of Experts Council)
В. Т. Ивашкин, A. I. Ulyanin, I. V. Mayev, et al.
Russian Journal of Gastroenterology Hepatology Coloproctology (2022) Vol. 32, Iss. 6, pp. 7-19
Open Access | Times Cited: 4
Intraluminal Therapy for Helicobacter pylori Infection—Comparison of Medicament Containing Tetracycline, Metronidazole, and Bismuth versus Amoxicillin, Metronidazole, and Clarithromycin: A Randomized Controlled Study
Ting-Wen Liu, Yen‐Po Chen, Cheng‐Yu Ho, et al.
Biomedicines (2023) Vol. 11, Iss. 4, pp. 1084-1084
Open Access | Times Cited: 1
Acid-Lowering Drugs for the Treatment of Gastro-esophageal Reflux Disease
Carmelo Scarpignato
Springer eBooks (2022), pp. 273-305
Closed Access | Times Cited: 2
Efficacy of potassium-competitive acid blockers vs. proton pump inhibitors on gastric ulcers: Bayesian and frequentist network meta-analysis with cross-inference through a quality management system
Hojin Oh, Kwanghyun Kim, Kwan-Haeng Lee, et al.
Research Square (Research Square) (2022)
Open Access | Times Cited: 2
Editorial: slow progress to optimising H. pylori eradication treatment with antisecretory drugs
Javier P. Gisbert, Richard H. Hunt
Alimentary Pharmacology & Therapeutics (2022) Vol. 56, Iss. 6, pp. 1074-1075
Closed Access | Times Cited: 1
Comparative Study Between the Efficacies of Vonoprazan Versus Omeprazole in Patients with Gastroesophageal Reflux Disease
Mohammed Mahdi, Amgad Al-Zhaby, Mohamed B. Abdelhalim, et al.
International Journal of Medical Arts (2023) Vol. 5, Iss. 1, pp. 2958-2966
Open Access
Page 1

Scroll to top